Psychosis-Risk Outcomes Network (ProNET)
ProNET is an international network established under the framework of Accelerating Medicines Partnership Schizophrenia (AMP SCZ). The ProNET network comprises 28 international sites across the United States, Canada, Italy, Germany, Spain, England, China, and South Korea. The sample includes individuals at clinical high risk for psychosis syndrome. Participants are between the ages of 12 and 30 years old, and are noticing a recent change in their thinking, behavior, or experiences. Participants then undergo a clinical interview about four times a year, as well as biological assessments, and cognitive testing.
Study design
Cohort
Number of participants at first data collection
260 (controls)
1,040 (CHR participants)
Recruitment is ongoing
Age at first data collection
12 - 30 years (participants)
Participant year of birth
Varied (participants)
Participant sex
All
Representative sample at baseline?
No
Sample features
Countries
Year of first data collection
2022
Primary Institutions
University of California, Los Angeles (UCLA)
Yale University
Zucker School of Medicine
Profile paper DOI
Not available
Funders
Accelerating Medicines Partnership (AMP)
Foundation for the National Institutes of Health (FNIH)
National Institutes of Health (NIH)
Ongoing?
Yes
Data types collected
- Audio or visual recordings (e.g. of child behaviour, facial expressions)
- Computer, paper or task testing (e.g. cognitive testing, theory of mind doll task, attention computer tasks)
- Interview – online
- Passive electronic data collection (e.g. screen time, scroll speed)
- Physical or biological assessment (e.g. blood, saliva, gait, grip strength, anthropometry)
- Self-report questionnaire – online
- Wearable devices
- Creative, arts-based and visual methods
- Interviews or focus groups
- Electroencephalography (EEG)
- Functional magnetic resonance imaging (fMRI)
- Magnetic Resonance Imaging (MRI)
- None
Engagement
Keywords
